NVIV InVivo Therapeutics Holdings Corp

InVivo Therapeutics to Present at Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California. The company’s presentation will be on October 6 at 4:00 PM (PDT). A live webcast will be available at http://www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine (ARM)’s website shortly after the event.

Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts: the program’s two-day Partnering Forum, a public forum lecture, and a full-day scientific symposium.

Dr. Ulich said, “We look forward to sharing the latest news about our Neuro-Spinal Scaffold™ and Bioengineered Neural Trails™ with the community.”

This year’s event is expected to attract more than 800 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations, disease philanthropies, and life science media.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

EN
26/09/2016

Underlying

NVIVInVivo Therapeutics Holdings Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InVivo Therapeutics Holdings Corp

 PRESS RELEASE
Free
NVIV InVivo Therapeu...

InVivo Therapeutics Reports 2018 First Quarter Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo gained significant momentum in the first quarter of 2018, and we look forward to building on our positive momentum throughout the rest of the year. We remain focused on the development of our Neuro-Spinal Scaffold™ and continue to take steps to re...

May 7, 2018 1 EN
 PRESS RELEASE
Free
NVIV InVivo Therapeu...

InVivo Therapeutics Announces Presentation of Complete Six-Month Prima...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the presentation of the complete six-month primary endpoint results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at a medical meeting. The presentation was given by Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, at the 2018 AANS Meeting during the Plenary Session II ...

May 2, 2018 1 EN
 PRESS RELEASE
Free
NVIV InVivo Therapeu...

InVivo Therapeutics Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV) today provided a general business update. The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 16, 2018, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the Company's existing trading symbol, "NVIV," at the market open on Apri...

April 9, 2018 1 EN
 PRESS RELEASE
Free
NVIV InVivo Therapeu...

InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study includes neurological recovery data from registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE study. Specifically, only patients injured between 2006 and 2016 and meeting inclusion and exclusion criteria si...

March 19, 2018 1 EN
 PRESS RELEASE
Free
NVIV InVivo Therapeu...

InVivo Therapeutics Reports 2017 Year-end Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2017. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo is charting a new and exciting path forward based on collaboration with the FDA that has continued through 2017 and into this year. We were pleased to announce last week that we received the agency’s approval of our supplemental Investigational Device Exemption (IDE) to initiate a second pi...

March 12, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch